Contrarian Value Ideas

[gfp927z]

TEVA - >>> While Teva has dramatically reduced fiscal 2017 guidance, we do not expect the core challenges they are facing to fade anytime soon. Pricing pressure and increased competition in the U.S. generics business will remain, the appointment of a full-time chief executive is still pending and the threat of generic competition to Copaxone 40 milligram (mg) still looms. Reports around potential non-core asset sales to pay down debt are encouraging, but we wait to see the final details of the transactions before giving Teva full credit. Upside risks could come from appointment of a credible CEO and attractive terms on assets disposals, helping to stabilize Teva’s story. <<<


http://www.barrons.com/articles/down-with-teva-up-with-portola-1503673394